Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Beats Expectations By $0.15 EPS

by · The Cerbat Gem

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15, Zacks reports. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Capricor Therapeutics Price Performance

NASDAQ:CAPR traded up $0.61 during trading hours on Wednesday, hitting $12.22. The company had a trading volume of 1,027,458 shares, compared to its average volume of 1,364,117. The stock has a 50-day moving average price of $14.09 and a 200 day moving average price of $14.51. The company has a market capitalization of $555.64 million, a PE ratio of -11.53 and a beta of 4.10. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Check Out Our Latest Stock Analysis on CAPR

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also